Arronax’s in-house hospital radiopharmacy is providing all the radiopharmaceutical doses planned for the dose escalation phase of an innovative clinical trial aimed at treating castration-resistant prostate cancer.
The aim of the study is to assess the safety, tolerability, pharmacokinetics and anti-tumour activity of a molecule labelled with actinium 225, which represents a new therapeutic approach for patients with castration-resistant metastatic prostate cancer. This alpha therapy trial is a world first.
Centralised production of clinical doses is carried out in the new radiopharmaceutical manufacturing room of the in-house hospital radiopharmacy, located on the Arronax premises. This state-of-the-art facility, which complies with Good Manufacturing Practice (GMP), guarantees compliance with the most stringent standards and helps to ensure the quality of the drugs prepared, reflecting the highest standards of safety and quality.
The R&D stages prior to the launch of this trial were also carried out at Arronax.
Dose production began in January 2024 at Arronax.
Credit: GIP ARRONAX
Contact: Arronax’s in-house hospital radiopharmacy team